key: cord-0936523-2fydojpz
authors: Hancock, Trevor J.; Hickman, Peyton; Kazerooni, Niloo; Kennedy, Melissa; Kania, Stephen A.; Dennis, Michelle; Szafranski, Nicole; Gerhold, Richard; Su, Chunlei; Masi, Tom; Smith, Stephen; Sparer, Tim E.
title: Possible Cross-Reactivity of Feline and White-Tailed Deer Antibodies against the SARS-CoV-2 Receptor Binding Domain
date: 2022-03-30
journal: J Virol
DOI: 10.1128/jvi.00250-22
sha: 235c17c7f4fb3e02af5530876f01df9fab2a7ec3
doc_id: 936523
cord_uid: 2fydojpz

In late 2019, a novel coronavirus began circulating within humans in central China. It was designated SARS-CoV-2 because of its genetic similarities to the 2003 SARS coronavirus (SARS-CoV). Now that SARS-CoV-2 has spread worldwide, there is a risk of it establishing new animal reservoirs and recombination with native circulating coronaviruses. To screen local animal populations in the United States for exposure to SARS-like coronaviruses, we developed a serological assay using the receptor binding domain (RBD) from SARS-CoV-2. SARS-CoV-2’s RBD is antigenically distinct from common human and animal coronaviruses, allowing us to identify animals previously infected with SARS-CoV or SARS-CoV-2. Using an indirect enzyme-linked immunosorbent assay (ELISA) for SARS-CoV-2’s RBD, we screened serum from wild and domestic animals for the presence of antibodies against SARS-CoV-2’s RBD. Surprisingly prepandemic feline serum samples submitted to the University of Tennessee Veterinary Hospital were ∼50% positive for anti-SARS RBD antibodies. Some of these samples were serologically negative for feline coronavirus (FCoV), raising the question of the etiological agent generating anti-SARS-CoV-2 RBD cross-reactivity. We also identified several white-tailed deer from South Carolina with anti-SARS-CoV-2 antibodies. These results are intriguing, as cross-reactive antibodies toward SARS-CoV-2 RBD have not been reported to date. The etiological agent responsible for seropositivity was not readily apparent, but finding seropositive cats prior to the current SARS-CoV-2 pandemic highlights our lack of information about circulating coronaviruses in other species. IMPORTANCE We report cross-reactive antibodies from prepandemic cats and postpandemic South Carolina white-tailed deer that are specific for that SARS-CoV RBD. There are several potential explanations for this cross-reactivity, each with important implications to coronavirus disease surveillance. Perhaps the most intriguing possibility is the existence and transmission of an etiological agent (such as another coronavirus) with similarity to SARS-CoV-2’s RBD region. However, we lack conclusive evidence of prepandemic transmission of a SARS-like virus. Our findings provide impetus for the adoption of a One Health Initiative focusing on infectious disease surveillance of multiple animal species to predict the next zoonotic transmission to humans and future pandemics.

We report cross-reactive antibodies from prepandemic cats and postpandemic South Carolina white-tailed deer that are specific for that SARS-CoV RBD. There are several potential explanations for this cross-reactivity, each with important implications to coronavirus disease surveillance. Perhaps the most intriguing possibility is the existence and transmission of an etiological agent (such as another coronavirus) with similarity to SARS-CoV-2's RBD region. However, we lack conclusive evidence of prepandemic transmission of a SARS-like virus. Our findings provide impetus for the adoption of a One Health Initiative focusing on infectious disease surveillance of multiple animal species to predict the next zoonotic transmission to humans and future pandemics.

KEYWORDS ELISA, RBD, SARS-CoV-2, antibodies, bovine, canine, coronavirus, crossreactive, feline, white-tailed deer other coronaviruses within the spike protein (32) , but antibodies against the S2 subunit can cross-react with common human coronaviruses (46) (47) (48) . Cross-reactivity of the S1 subunit occurs at very low rates. Within the S1 region, the RBD is highly immunogenic and unique to SAR-COV/SARS-CoV-2 (32, 49) . Serum from humans infected with common human coronaviruses such as OC43, NL63, and 229E failed to recognize the RBD from SARS-CoV-2 (32, 46, 49) . Animals infected or immunized with other coronaviruses similarly fail to generate cross-reactive antibodies against SARS-CoV-2's RBD (32) . For infected cats, SARS-CoV-2 seroconversion was not impacted by preexisting immunity against feline coronavirus (FCoV), an alpha-coronavirus with limited similarity to SARS-CoV-2 (38) . Collectively, seropositivity against the RBD of SARS-CoV-2 is a specific marker of SARS-CoV-2 exposure and has led several groups to create highly specific indirect enzyme-linked immunosorbent assays (ELISAs) against SARS-CoV-2's RBD to screen for SARS-CoV-2 exposure (30, 32, 33) . A final consideration of antibodies targeting the RBD is whether they are neutralizing or nonneutralizing (33, (50) (51) (52) (53) . For example, serum from humans and animals exposed to the original SARS-CoV were able to recognize the spike and RBD of SARS-CoV-2, while their cross-neutralization potential was variable (54, 55) .

Despite limited similarity in the spike protein of SARS-CoV-2 versus common circulating coronaviruses, there are reports of prepandemic, preexisting SARS-CoV-2 reactive serum in humans (48, 49, 54) . These cross-reactive antibodies represent a rare response to common human coronaviruses within conserved epitopes of SARS-CoV-2's spike protein (usually in the S2 region) with reports of ;0.6% prevalence of preexisting anti-RBD responses (46, 48, 49) . Although there is increasing evidence for earlier timelines of SARS-CoV-2 spread among humans, preexisting seropositivity among other species has not been reported (38, (56) (57) (58) . Indeed, even within central China, researchers failed to find evidence of SARS-CoV-2 exposure prior to the pandemic (38, 56, 58) .

As SARS-CoV-2 spreads and encounter's new species, there is a need for monitoring local populations for SARS-CoV-2 transmission and the potential establishment of local reservoirs. Currently, we have a limited understanding of coronavirus reservoirs, spread, and recombination among diverse species. The original SARS outbreak in 2003 was a harbinger of the potential risk of crossover coronaviruses. At that time, animal coronavirus surveillance was a high priority. Unfortunately, this investment was not sustained. Our aim was to address whether SARS-CoV-2 is being introduced into companion animals of North America by tracking seroconversion using an in-house indirect ELISA against the RBD of SARS-CoV-2. We chose to focus on companion animals (i.e., cats and dogs), as they represent a significant source of human-animal interactions with potential for contact and further spillover into wild animal populations. Surprisingly, we found evidence of anti-RBD seropositive animals predating the pandemic by several months to years. Our study provides evidence for the existence and prevalence of SARS-CoV-2 serum reactivity prior to the current pandemic.

We developed an in-house ELISA to serologically screen companion animals based on a protocol developed at Mt. Sinai (30, 59) . To examine cross-reactivity of our inhouse anti-SARS-CoV-2 RBD indirect ELISA, we used polyclonal guinea pig serum raised against different animal coronaviruses (Fig. 1A) . Consistent with previous reports, no cross-reactive antibodies for any of the common coronaviruses were found (18, 32, 38, 56) . Only antibodies from SARS-CoV-or SARS-CoV-2-infected individuals reacted ( Fig.  1A and B) . Human serum collected from individuals prior to the SARS-CoV-2 pandemic or plasma from recovered SARS-CoV-2 donors was used to validate our ELISA screen (Fig. 1B) . Receiver operator curve (ROC) analysis determined the positive cutoff threshold, using a value that gave highest specificity and sensitivity with prepandemic human serum and serum from confirmed SARS-CoV-2 infected individuals. ROC analysis was in agreement with the commonly used threshold determination method of three standard deviations above the mean negative value. Our assay based on RBD screening showed high sensitivity (96.96%) and specificity (95.45%) with 66 SARS-CoV-2 samples and 22 pre-SARS-CoV-2 samples (Fig. 1B) . While Stadlbauer et al. (59) performed two diagnostic ELISAs, one with RBD and the other with full-length spike, our results using only the RBD-based screen are in good agreement with their published FIG 1 Anti-SARS-CoV-2 ELISA sensitivity and specificity. (A) Cross reactivity of anti-CoV antibodies against SARS-CoV-2 RBD. Polyclonal sera from guinea pigs immunized with common animal coronaviruses (turkey coronavirus, TCoV; porcine respiratory coronavirus, PRCoV; canine coronavirus, CCoV; feline coronavirus, FCoV; bovine coronavirus, BCoV) were used in a SARS-CoV-2 RBD indirect ELISA. Positive samples consisted of polyclonal serum from a SARS-CoV-2-infected patient and a monoclonal antibody to SARS-CoV (CR3022). The negative-control group comprised prepandemic human sera. Secondary antibodies were either anti-human IgG (1:10,000) (Rockland Immunochemicals, USA) or anti-guinea pig IgG (1:10,000) (Life Technologies Corp., USA). Bars represent the mean and standard deviation (n . 3 for all samples). (B) ELISA validation using 66 human COVID-positive plasma and 22 negative serum samples. Human antibodies against the SARS-CoV-2 RBD were detected with an indirect RBD-specific ELISA. Secondary antibody was the anti-human IgG (1:10,000) (Rockland Immunochemicals, USA). ROC analysis determined the positive OD 450 cutoff value (dashed line). Positive plasma samples were donated by COVID-recovered patients, and prepandemic serum samples were the negative controls. Based on the experimentally determined cutoff value, 64 of the 66 positive samples were anti-RBD positive, giving a sensitivity value of 96.96%. All but one of the negative samples were below the cutoff value for a specificity of 95.45%. The adjacent tables list the first and third quartiles along with mean and median OD 450 values of COVID-positive and -negative human samples. Bars represent the mean and standard deviation (n . 3). (C) Anti-6ÂHis Western blot on HEK-293T17 purified RBD from 5% serum conditions. Samples were run on a 12% denaturing SDS-PAGE gel. Protein was transferred to nitrocellulose and probed with anti-6ÂHis antibody at 1:10,000 (Proteintech, USA). White light and chemiluminescent images were overlaid and from left to right, are ladder (lane 1) and purified RBD (lane 2). (D) Silver stain of purified recombinant SARS-Cov-2 RBD produced in HEK-293T17. From left to right, ladder, HEK-RBD under 5% serum conditions, HEK-RBD from 2% serum conditions. Samples were denatured and run on a 12% SDS-PAGE gel and silver-stained (Thermo Fisher Scientific, USA). For panels B and C, representative data are shown.

data. Others have also demonstrated the accuracy of an RBD-only-based ELISA (33, 38) . A Western blot using an anti-6ÂHis antibody (Fig. 1C) shows the expected size of purified RBD with a single band of ;32 kDa. This shows that our isolated RBD is the correct size and runs as a monomer. Silver stain of the same affinity-purified SARS-CoV-2 RBD demonstrates relative purity (Fig. 1D) . However, there are copurified proteins present at lower levels.

To establish a baseline for future SARS-CoV-2 screening of companion animals, 128 prepandemic feline serum samples collected prior to December 2019 were retrospectively screened using our in-house ELISA. A total of 19 samples were of a known FCoV serological status, with the remaining 109 of unknown FCoV status. Following the same protocol used for screening human serum samples (Fig. 1 ), feline samples were tested for antibodies against SARS-CoV-2's RBD ( Fig. 2A) . There were two batches tested, serum samples from feral cats in East Tennessee collected from 2007 to 2012 (n = 36) and convenience samples from client-owned cats undergoing routine blood work (listed as prepandemic) (n = 92) ( Fig. 2A) . As expected, SARS-CoV-2 experimentally infected cats (14) tested positive with high relative optical density at 450 nm (OD 450 ) and normal cat serum (i.e., negative control), with very low relative OD 450 ( Fig.  2A) . Despite predating the pandemic, 52% (67/128) of the cat samples tested positive for antibodies against SARS-CoV-2 RBD. This is surprising, as there was a lack of high cross-reactivity in guinea pigs immunized with FCoV in Fig. 1A . Several reports also showed a lack of similarity and cross-reactivity between alpha coronaviruses and SARS-CoVs (18, 32, 38, 56) . Indeed, two other groups found that preexisting immunity to FCoV had no impact on seropositivity of feline samples (38, 58) . To ensure that the positive ELISA results were specific to the RBD and not to a copurified protein, Western blot analysis was carried out using serum from a positive sample (Fig. 2B ). Positive cat serum bound an ;32-kDa protein, the size of the RBD protein (Fig. 1C) . Notably, normal cat serum did not react with any other protein despite the presence of copurified proteins. To further show the specificity of the anti-RBD response, we titrated seropositive and seronegative samples. Starting with serum from cats experimentally infected with SARS-CoV-2 ( Fig. 2A) and normal cat serum, we saw a normalized OD 450 .3 standard deviations above the negative control (i.e., normal cat serum) at all dilutions. This gives a titer of .8,100 (Fig. 2C) . Then, 17 seropositive and 10 seronegative pre-2020 cat samples were titrated and assayed in our ELISA (Fig. 2D ). Titers ranged from 900 to 8,100, with a median titer of 2,700 demonstrating both a high anti-SARS RBD prevalence and titer. Titrations of these earlier seropositive and seronegative feral cat samples have a similarly high titer ( Fig. 2E ) (median titer, 8,100) which is on par with the prepandemic samples. The area under the curve (AUC) for all groups is shown to the right side of their respective titration. AUC analysis of the titrated samples showed a significant difference between all positive and negative samples.

Following the surprising presence and prevalence of anti-RBD responses in prepandemic cats, we explored the epidemiological characteristics of our samples. Prepandemic convenience samples were submitted to the University of Tennessee for diagnostic testing of feline herpesvirus, feline calicivirus, and FCoV. Age, sex, and location of seropositive and seronegative samples are shown in Table 1 . Both seropositive and seronegative samples had a mean age of .3 years with no difference between the groups and contained similar ratios of male:female animals (Table 1) . Seropositive samples were found in disparate geographic locations from opposite coasts of the United States (i.e., New York to California [ Table 1 ]). This observation indicates that seropositivity is not confined to a single geographic region (e.g., East Tennessee). Based on our limited sampling, we were unable to identify any unique characteristic or identifier for seropositive versus seronegative samples.

With our discovery of preexisting antibodies against SARS-CoV-2's RBD, it was pertinent to examine samples from dogs, another companion animal with high human contact. Serum samples from dogs (n = 36) were collected and retrospectively screened as part of a tick study during a 7-month period beginning in January 2020 and extending into July 2020. These samples are considered postpandemic because the time frame straddles the arrival of SARS-CoV-2 in East Tennessee (;March 2020). The initial ELISA screen identified 97% seropositivity in the dog samples ( Fig. 3A) , with only 1 sample falling below the cutoff established on human serum. Surprisingly, serum from purpose-bred research animals housed at the University of Tennessee also showed high levels of reactivity (Fig. 3A) . This raised suspicion about the specificity of the response. To address this, Western blot analysis with canine serum (Fig. 3B ) identified a protein other than the RBD (see the ;32-kDa protein in Fig. 1C and 2B). The canine serum recognized an ;60-kDa protein which is likely a copurified protein present after RBD purification and is faintly seen in the silver-stained gel in Fig. 1D . This copurified protein was not detected in the blots performed for Fig. 1C and 2B using anti-6ÂHis monoclonal antibody and cat serum, respectively. Although there is a possibility that canine serum recognizes an oligomer of RBD (60), based on Fig. 1C , the anti-6ÂHis antibody does not detect any protein of .32 kDa, eliminating this possibility. Following our observation of high levels of anti-SARS-CoV-2 RBD antibodies in North American cats, we began examining other regional animals. Serum samples from Tennessee resident, prepandemic cows (n = 33) and tigers (n = 9), postpandemic East Tennessee elk (n = 12), and postpandemic South Carolina white-tailed deer (n = 22) were tested for anti-SARS-CoV-2 RBD antibodies (Fig. 4A) . Of the four species tested, only the deer from South Carolina showed any seropositive samples (2/22). Serum titrations show the two seropositive samples have a high titer of .8,100 (Fig.  4B) , and the AUC of the titrations show a significant difference between seropositive and negative deer samples (Fig. 4C ). Unfortunately, due to limited sample volume, we were unable to run Western blots to demonstrate the specificity for the RBD protein.

The deer are postpandemic and could represent recent transmission of SARS-CoV-2 into the deer population. Although these animals probably have had limited contact with humans, white-tailed deer are susceptible to and capable of transmitting SARS-CoV-2 (61). Another possibility is that this species was exposed to the same etiological agent as our prepandemic seropositive cats.

To address whether our ELISA-positive animal samples can neutralize SARS-CoV-2 infections, we measured the ability of cat serum to block the interaction of the spike protein with the human ACE-2 (hACE-2) receptor using a commercially available flow cytometry-based bead assay. In this assay, neutralization is characterized as the decrease in fluorescence when antibodies block the fluorescently labeled SARS-CoV-2 S1 subunit from binding to hACE-2 conjugated beads (Fig. 5A) . Because this assay is not species specific or immunoglobulin type dependent, it is applicable for assessing both human and feline serum. The internal antibody control shows a decrease in fluorescence corresponding to levels of neutralizing monoclonal antibody against SARS-CoV-2. Serum from experimentally infected cats showed potent neutralization at a 1:100 dilution. However, only one ELISA-positive, prepandemic cat sample showed neutralization (Fig. 5B) . One of the seropositive white-tailed deer samples and a single serum sample from mice immunized with porcine respiratory coronavirus (PRCoV) also showed slight neutralization, clearing the determined ROC threshold/cutoff value (Fig.  5B) . Notably, we were unable to detect high levels of neutralization/neutralizing antibodies even in several of the human convalescent-phase serum samples (Fig. 5B) .

Because cross-reactivity of antibodies to SARS-CoV-2 RBD independent of SARS-CoV-2 infection has not been previously reported in felines, we suspected that the etiological agent could be another coronavirus (38, 58) . Fecal samples were collected from healthy East Tennessee cats and screened for coronaviruses using pan-coronavirus primers amplifying conserved regions of the RNA-dependent RNA polymerase (RdRp), helicase (Hel), and spike (S) genes (62) . Coronavirus viral RNA, whether common animal coronavirus or SARS-like coronavirus, is potentially shed in feces (8, 9, 11, 13) . Collection of fecal samples used a noninvasive collection method, and SARS-CoV-2 has been reported to have prolonged shedding within fecal samples of humans (8, 9, 11, 13) . Out of 30 samples, 15 (50%) tested positive for at least one loci, with most yielding positive results for multiple loci ( Table 2 ). Not surprisingly, sequences cluster within the alpha-coronavirus group and with high similarity to previously identified FCoV strains. When all five loci were aligned and concatenated together, the maximum-likelihood phylogenetic tree placed the concatenated coronavirus sequences within the alpha-coronavirus lineage, closely related to FCoV (Fig. 6A ). We were unable to amplify or identify any sequences which resemble SARS-like coronaviruses or beta-coronaviruses. Partial sequencing of the S1 region was able to amplify the RBD from several coronavirus RNA-positive samples. The sequenced RBDs were again highly similar to FCoV based on a maximum-likelihood phylogenetic tree (Fig. 7A) . Along with the phylogenetic tree, a similarity matrix demonstrates high RBD similarity between previous FCoV strains and those sequenced here (;80%) (Fig. 7B ). The RBD from these fecal samples displays low similarity to betacoronaviruses such as Middle East respiratory syndrome (MERS), SARS-CoV, and SARS-CoV-2 (;30%) as previously reported (Fig. 7B) . , and human serum samples (Covid1, convalescent plasma from Covid1 humans; Covid-, pre-SARS-CoV-2 serum samples; vaccine, serum postvaccination against SARS-CoV-2 spike protein) were used. SARS-CoV-2-infected cats and normal cat serum served as positive and negative controls, respectively. Data were normalized to normal cat serum representing 100% binding of SARS-CoV-2 S1 subunit to hACE2 beads. ROC analysis was used to generate a positive reduction threshold (dotted line). Each point is an average of 2 replicates. Tukey's one-way ANOVA with multiple comparisons was used to analyze experimental groups. *, P , 0.05; ****, P , 0.0001.

We have employed serological screening as a method to detect potential SARS-CoV-2 exposure in animal populations. Tracking active viral spread in wild and domesticated animals in real-time via sequencing and reverse transcriptase quantitative PCR (RT-qPCR) is expensive and low throughput. In addition, the unknown transient nature of viral shedding from different secretions/locations makes this type of surveillance prohibitively expensive with no guarantee of identifying a virus. Serological detection of antibodies against SARS-CoV-2 is comparatively high-throughput and inexpensive while still maintaining sensitivity. A downside of this methodology is the lack of an upto-date picture of cross-species transmission, as serology trails initial infections by several days to weeks (22, 33) . On the other hand, due to the lowered cost of serological testing, there is a compensatory increase in testing capability allowing a broader swath of animals and regions to be sampled with more frequent resampling to track spillover into new species. Our adapted protocol yields recombinant SARS-CoV-2 RBD protein, allowing production of a low-cost indirect anti-RBD ELISA. The recombinant RBD was sufficient for serological screening via ELISA and is amenable to most labs with prior tissue culture capabilities and does not require large initial investments in cell lines, culture media, or specialized incubators. We validated our method demonstrating low cross-reactivity with other common animal coronaviruses (Fig. 1A) and .95% sensitivity and specificity on human serum samples (Fig. 1B) .

For the seropositive samples identified in our study, mean titers for positive cat samples were relatively high at ;2,700 ( Fig. 2E and G) , which based on reported rapid declines in anti-RBD responses for SARS-CoV and FCoV, points to exposure within the past few years (37, 38, 40) . Further, based on FCoV studies, animals with high titers typically correlate with active viral shedding and spread within a household, which highlights a potential overlap between seropositivity and viral shedding (37) . This is in stark contrast to SARS-CoV-2 serosurveys on pre-and postpandemic feline samples from Central China. They found no evidence of exposure before the outbreak, but also, positivity levels postpandemic were significantly lower than those shown here (;12% in Central China versus .50% in the United States) ( Fig. 2A ) (38, 58) . OD 450 and titers of prepandemic seropositive cat samples, while high, were lower than SARS-CoV-2-experimentally inoculated cats (6 weeks postinfection) ( Fig. 2A, C, E, and G) . This likely represents a natural decline in titer over time for the environmental samples but could also represent lower titers of cross-reactive antibodies from another coronavirus. Unfortunately, dog serum was shown to bind to a copurified protein (Fig. 3B) , leaving us unable to utilize our assay for examining cross-species transmission of SARS-like coronaviruses to canines. We can show that recombinant RBDs produced and purified by groups at both Mt. Sinai and Emory contain copurified proteins at approximately the same size as those shown in Fig. 1A (30, 33) . As such, screens for SARS-CoV-2 exposure in canines would likely require producing and purifying the RBD using a different strategy that eliminates non-RBD protein contamination. Recently, both SARS-CoV-2's RBD and soluble full-length spike have been produced and purified in plants (63) . This alternative method may prove useful for animal SARS-CoV-2 screening by reducing or eliminating false positives due to copurified proteins.

After the discovery of prepandemic seropositive cats, we examined other commercial (cow) and convenience samples from local wild species (deer, elk, tiger) (Fig. 4A) . Out of 22 white-tailed deer from South Carolina, 2 (9%) were positive for antibodies against the RBD (Fig. 4B) . Unlike our cat samples, the two seropositive deer could represent transmission of SARS-CoV-2 into the local deer population because these samples were collected postpandemic. Interestingly, a recent report showed that ;40% of white-tailed deer from 4 states (Illinois, Michigan, New York, and Pennsylvania) were positive for SARS-CoV-2 antibodies (29) . Seropositive animals were only observed from 2019 onward, with prepandemic deer testing negative on their SARS-CoV-2 neutralization assay. This information supports our finding in South Carolina deer (Fig. 4) . SARS-CoV-2 sequences were also recently isolated from the retropharyngeal lymph nodes of wild and captive deer (27, 28) . The dominant genotype of deer-isolated SARS-CoV-2 genotypes closely corresponded to those circulating within humans at the time, pointing to potential rapid transmission from humans to animals (28) . This highlights the importance of the One Health Initiative to provide information on the potential exposure and spillover into other species and the question of whether there is recombination with native coronaviruses occurring to generate new variants or establishment of new reservoirs in North America. Further work is needed to determine the prevalence, spread, and identity of SARS and other coronaviruses circulating within North American deer and associated species.

That samples from cats experimentally infected with SARS-CoV-2 displayed potent neutralization (Fig. 5B) is unsurprising because of their high ELISA titers (Fig. 2C) . These samples were collected at ;8 weeks postinfection and likely represent peak titer and neutralization capacity (14) . Neutralization of SARS-CoV-2 S1 subunit was variable for environmental feline ELISA-positive samples (Fig. 5B) . There was no significant difference in mean fluorescent intensity (MFI)/neutralization between the anti-RBD seropositive and seronegative feline samples (Fig. 5B) . Even sera from convalescent, COVIDrecovered individuals showed no to minimal neutralization (Fig. 5B) . Several groups have found that not all anti-RBD responses generate neutralizing antibodies (50) (51) (52) (53) 64) . Indeed, even in convalescent-phase serum, high levels of RBD recognition do not guarantee high neutralizing titers, consistent with our own observations (Fig. 5B) (50) . Based on ELISA and neutralization results ( Fig. 2A and 5B) , we suspect that these animals contain antibodies recognizing SARS-CoV-2's RBD but likely bind to nonneutralizing epitopes of the RBD domain.

Because ;50% of cats surveyed were seropositive, we reasoned that isolation of the suspected infectious agent or coronavirus might be possible. Based on fecal viral RNA shedding following animal coronavirus infections, PCR amplification with universal coronavirus primers was used to screen for potential causative agents of anti-RBD seropositivity. This allowed for noninvasive testing and isolation of coronavirus RNA from infected cats. In line with previous studies on other wild animals, we did not identify any nonalphacoronaviruses circulating in felines (65) (66) (67) (68) . The coronavirus sequences that were isolated and sequenced likely represent normal circulating FCoVs (Fig. 6) . Due to the opportunistic nature of our sampling, we were unable to obtain any paired blood and fecal samples from the same animal. As such, we are unable to conclude whether the cats with identified FCoVs would produce cross-reactive antibodies against SARS-CoV-2's RBD. However, based on our ELISA results in Fig. 1A and 2A showing no correlation with SARS RBD antibodies and FCoV infection, we would suspect not. Furthermore, as we did not know when the seropositive cats were exposed (i.e., cats could have been infected potentially years prior to any fecal sampling), fecal sampling and sequencing would not detect a novel coronavirus if it had been cleared. Following the identification of coronavirus-positive fecal samples, we attempted to amplify and sequence the entire RBD region from positive samples to look for similarity to SARS-CoV-2 or SARS-like viruses. Large portions of the S1 region spanning the RBD were sequenced and contained RBD regions similar to previously isolated FCoV strains (Fig. 7) , with no similarity to SARS or betacoronaviruses.

The current study demonstrates cross-reactivity of prepandemic feline samples with the RBD of SARS-CoV-2. Our indirect ELISA screen has provided evidence for seropositivity of serum from North American cats and deer to a SARS-CoV-2 protein previously shown to be highly specific to SARS coronaviruses (32, 38, 46, 49) . This is the first study to demonstrate seropositivity of animal samples prepandemic. What induces this cross-reactive response was not readily apparent. However, we propose several possibilities-exposure to another infectious agent generating cross-reactive antibodies, infection with multiple common coronavirus strains (feline coronavirus or otherwise) generating cross-reactive antibodies, or exposure of animals to a SARS-like coronavirus prepandemic. There is evidence both for and against these explanations for the seropositivity observed. While we cannot discount a noncoronavirus infection generating cross-reactive antibodies, the RBD of SARS-like viruses is thought to be unique with no previous evidence of RBD cross-reactivity (32, 38, 46, 49) . A plausible explanation for seropositivity against SARS-CoV-2's RBD is infections with coronaviruses generating an atypical response. To date, cross-reactivity against the RBD of SARS-CoV-2 has only been reported for SARS and SARS-like coronaviruses (32, 46) . The common human and animal coronaviruses (both Alphaand Betacoronavirus families) individually do not generate cross-reactive antibodies against this protein, presumably making it a SARS-specific response (30, 32, 33, 38, 46, 49) . For example, prior FCoV exposure did not impact SARS-CoV-2 RBD recognition (38) . Our own observations further demonstrated that FCoV (both serotype I and II) and transmissible gastroenteritis virus (TGEV) did not correlate with serostatus for SARS-CoV-2's RBD ( Fig. 2A) (FCoV1, FCoV-) . Additionally, humans and animals are exposed to multiple coronaviruses throughout their lifetime, generating measurable immune responses to antigenic proteins (69, 70) . With humans, CoV infections occur on average once a year, with protective immunity appearing to wane a few months after initial exposure (69, 70) . Despite reports of cross-reactivity toward portions of SARS-CoV-2's spike protein induced by other human coronaviruses, there have been no reports of cross-reaction against the distinct RBD region (32, 46, 49) . While it does not disprove multiple CoV infections generating cross-reactive antibodies, it does cast doubt on this possibility. This leads us to propose prior exposure to a SARS-like coronavirus for North American cats.

There is limited evidence to support prior transmission of a SARS-like virus within felines. However, cats are susceptible to infection and transmission of SARS-CoV-2 (14) . SARS coronaviruses evolved from bat coronaviruses and maintain a high degree of sequence similarity, even in the RBD region (32) . Conceivably, our definition of SARSlike coronavirus could also encompass bat coronaviruses due to amino acid similarity and potential cross-reactivity in the RBD region. At least in Tennessee there are numerous cave systems with several native species of bats, potentially leading to an interspecies transmission. Feline and bat interactions could lead to direct transfer of a SARS-like agent, or an intermediary species could be involved. North American deer mice were recently shown to be susceptible to human SARS-CoV-2 and capable of mouse-to-mouse transmission, representing another potential point of introduction into the feline population (71) . The prepandemic exposure of cats to a SARS-like agent does have detractions. Other groups examining prepandemic samples have failed to find evidence of RBD-reactive serum even within Central China (38, 56, 58) . The ELISA-positive samples from our environmental samples (i.e., feline and deer) did not neutralize to the same degree as experimentally inoculated felines (Fig. 5B) (14) . However, significant neutralization was not observed for most samples, even convalescent-phase serum from COVID-positive individuals (Fig. 5B ). Despite ;50% seroprevalence in our samples, we were unable to identify any coronavirus sequences capable of eliciting an anti-SARS RBD response ( Fig.  6 and 7) . Additionally, there is currently no evidence of a circulating SARS-like or bat betacoronavirus in North America (65) (66) (67) (68) . While we cannot conclusively demonstrate the origin of the anti-RBD responses shown here, this study indicates that there could be a virus (or another infectious agent) that can generate cross-reactive antibodies to the SARS-CoV-2 RBD.

Limitations of the study. A major limitation of this study is the number of serum samples surveyed for all species. Due to the small sample size, we have refrained from making extrapolations from our data to larger animal populations or geographic regions. Similarly, a relatively small number of feline fecal samples were screened for coronavirus viral RNA (n = 30), limiting our ability to detect coronaviruses. Our choice of sampling source may have also limited our ability to detect novel coronaviruses or SARS-like coronaviruses. We chose to utilize fecal samples for coronavirus screening because it is noninvasive, animal coronavirus shedding within feces is common, and many are transmitted via the fecal to oral route. Additionally, SARS-CoV and SARS-CoV-2 viral RNA has been detected in stool samples of infected humans (8, 9, 11, 13) . This fecally shed RNA persists longer than nasal or oral sources (13) . However, sampling nasal/oral sources rather than fecal samples may allow for better detection of SARS-CoV-2. Indeed, isolation of SARS-CoV-2 RNA and whole-genome sequencing was possible from deer retropharyngeal lymph nodes (28) . Along with sampling site limitations, infection and shedding of viral RNA is a transient process with a relatively small window to detect and sequence the causative agent. While ;20 feline samples were tested for anti-FCoV antibodies, the majority of our samples were of an unknown FCoV status. Additionally, medical histories were not available for these animals, and they were not screened for prior exposure to other infectious agents. As such, we cannot definitively rule out some other infectious agent conferring the anti-RBD responses.

Conclusion. Our initial goal was to develop an ELISA for tracking the reverse zoonosis of SARS-CoV-2. However, when establishing our baseline on prepandemic cat samples, we discovered seropositive serum for an antigen previously reported to be SARS-specific (i.e., RBD). Seropositivity was ;50% in feline samples and could be found several years prior to the genesis of the current SARS-CoV-2 pandemic. What generated the RBD-reactive antibodies is unknown, but we proposed three possibilities, cross-reaction caused by another infectious agent, multiple coronavirus infections creating a rare cross-reactive antibody, and existence and circulation of a SARS-related virus containing the RBD sequence. Regardless, the high rate of SARS-CoV-2 RBD seropositivity within a common companion animal further highlights our need for a better understanding of the prevalence and crossover potential of wild coronaviruses. Further investigations should address shedding of viral RNA from the seropositive species (i.e., cats and deer) identified here to isolate, sequence, and identify the agent enabling cross-reactivity against the RBD of SARS-CoV-2.

Recombinant RBD production and purification. Recombinant RBD production has been previously published (56) . Our lab deviated from the prior published method to utilize equipment readily available. Briefly, the plasmid containing the RBD of SARS-CoV-2 was produced under federal contract HHSN272201400008C and obtained through BEI Resources, NIAID, NIH. Vector pCAGGS contains the SARS-related coronavirus 2, Wuhan-Hu-1 spike glycoprotein RBD, NR-52309. To produce recombinant RBD, the pCAGGS-RBD plasmid was transfected into ;5 Â 10 7 adherent HEK-293/T17 cells (ATCC CRL-11268) in a T-175 device using PEI (polyethylenimine, linear 25,000 molecular weight (m.w.) [Polysciences, Warrington, PA, USA]). Plasmid was mixed at a 1:3 ratio with PEI (20 mg of plasmid:60 mg PEI for a T-175 transfection) in 1 mL serum-free Dulbecco modified Eagle medium (DMEM) for 30 min at room temperature. Medium was aspirated, and the transfection mixture was added to 14 mL fresh growth medium and placed onto cells. Then, 3 to 4 h posttransfection, medium was changed and replaced with DMEM containing either 2% or 5% fetal bovine serum (HyClone FetalClone III; Cytiva Life Sciences, USA). Maintenance in a lower serum prevents overgrowth. However, we found higher protein yields with supplementation with 5% FBS. Transfection efficiency was nearly 100% as assessed by green fluorescent protein (GFP)-positive transfected cells in a control flask.

Supernatants from transfected HEK-293 T17 cells were collected into 50-mL conical tubes and frozen at days 3 and 6 posttransfection. Pooled supernatants were thawed and incubated with Ni-NTA (Ni-NTA agarose; Qiagen, Germany) resin with gentle rocking overnight. The resin was spun down at .3,400 Â g in a swing-bucket Sorvall RT centrifuge for 10 min at 4°C. Ni-NTA resin was resuspended in 1 mL wash buffer (20 mM imidazole, 5 mM NaH 2 PO 4 ÁH 2 O, and 0.3 M NaCl in H 2 O), transferred to a 2-mL microcentrifuge tube, gently rocked for 10 min at room temperature, spun, and resuspended in fresh buffer. Resin was washed between 3 and 7 times until the OD 230 was #wash buffer. Once the supernatant OD dropped sufficiently, 1 mL elution buffer (235 mM imidazole, 5 mM NaH 2 PO 4 ÁH 2 O, and 0.3 M NaCl in H 2 O) was added to elute the RBD from the nickel resin. Eluate was rocked for 10 min at room temperature and then centrifuged. Two elution steps were performed with a third final elution using 0.5 M imidazole. Protein concentration was determined by standard curve analysis of a silver-stained (Pierce silver stain kit; Thermo Scientific, USA) 12% SDS-PAGE gel using a standard curve of BSA (bovine serum albumin). Analysis was performed using Image Studio Lite ver. 5.3 (Li-Cor Biosciences, Lincoln, NE, USA).

Serum and plasma samples. Previously collected pre-SARS-CoV-2 deidentified human serum samples were kindly donated by Jon Wall and Steve Foster (University of Tennessee Medical Center, Knoxville, TN, USA). Deidentified COVID-positive plasma samples were donated from MEDIC Regional Blood Center (Knoxville, TN, USA) and Mark Slifka (Oregon Health Sciences University, Portland, OR, USA). The following reagents were obtained through BEI Resources, NIAID, NIH: human plasma, sample IDs WU353-073, NR-53643; WU353-074, NR-53644; WU353-075, NR-53645; WU353-076, NR-53646; and WU353-076, NR-53647, were initially contributed by Ali Ellebedy, Washington University School of Medicine, St. Louis, MO, USA. The following reagents were obtained through BEI Resources, NIAID, NIH: polyclonal anti-feline infectious peritonitis virus, 79-1146 (antiserum, guinea pig), NR-2518; polyclonal anti-canine coronavirus, UCD1 (antiserum, guinea pig), NR-2727; polyclonal anti-bovine coronavirus, Mebus (antiserum, guinea pig), NR-455; polyclonal anti-porcine respiratory coronavirus, ISU-1 (antiserum, guinea pig), NR-459; polyclonal anti-turkey coronavirus, Indiana (antiserum, guinea pig), NR-9465. Client-owned canine and feline serum samples were submitted to the University of Tennessee Veterinary Hospital for routine animal testing. Canine samples (n = 36) were collected postpandemic from local, East Tennessee animals. All feline samples were prepandemic. Samples from East Tennessee feral cats (n = 36) were collected from 2007 to 2012. Client-owned feline samples (n = 92) were collected nationwide as part of clinical diagnostic testing (see Table 1 ). Twenty cat samples were grouped into FCoV-positive and -negative groups based on feline infectious peritonitis (FIP) serology using an immunofluorescence assay (IFA) against FIP serotypes I and II, as well as TGEV (transmissible gastroenteritis virus) (VMRD, Pullman, WA, USA). Normal cat serum was purchased from Jackson ImmunoResearch (West Grove, PA, USA). Tennesseeresident cows (n = 33) and tigers (n = 9) were collected prepandemic for routine diagnostic testing. Postmortem, postpandemic samples were collected from East Tennessee elk (n = 12) and South Carolina white-tailed deer (n = 22).

Anti-RBD ELISA. Anti-RBD ELISA was based on the published protocol by Amanat et al. and Stadlbauer et al. (30, 59) . Purified RBD was diluted to 2 mg/mL in phosphate-buffered saline (PBS), and 50 mL was placed into each well of a 96-well plate (Immulon 4HBX, Thermo Fisher, USA) and allowed to incubate overnight at 4°C. Unbound RBD was removed, and wells were washed 3 times with PBS-T (PBS with 0.1% Tween 20). Rinsed wells were blocked with 5% milk in PBS for 2 h at room temperature. Block was removed and serum or plasma samples were added at a 1:50 dilution for the initial screen in PBS with 1% milk and incubated at room temperature for 1 h. After 1 h, wells were washed 3 times with PBS-T, and a secondary antibody for that species was added (i.e., horseradish peroxidase [HRP] goat anti-human IgG, Rockland Immunochemicals, Pottstown, PA, USA; HRP goat anti-dog IgG, Bethyl Laboratories, Montgomery, TX, USA; HRP goat anti-cat IgG, Invitrogen, Waltham, MA, USA; HRP goat anti-guinea pig IgG, Life Technologies Corp., Carlsbad, CA, USA; HRP rabbit anti-deer IgG, KPL, Gaithersburg, MD, USA; HRP sheep anti-cow IgG, Bethyl Laboratories, Montgomery, TX, USA) at dilutions of 1:10,000 (anti-human, -cat, -dog, -tiger) or 1:250 (anti-cow, -deer, -elk) in PBS with 1% milk. Optimal secondary antibody concentrations were determined by titration on either 5% milk (negative control) or a 1:50 dilution of that species serum (positive control). Secondary antibodies were allowed to incubate for 1 h at room temperature before being washed 3 times with PBS-T. ELISA was developed with 50 mL TMB (1-Step Ultra TMB-ELISA; Thermo Fisher, Waltham, MA, USA) for 10 min. Reactions were stopped by the addition of 2 M sulfuric acid and read using a BioTek Synergy 2 or Synergy H1 plate reader set at 450 nm (BioTek, Winooski, VT, USA). Receiver operator curve (ROC) analysis was performed to determine the appropriate threshold to yield 100% specificity of ELISAs performed at a 1:50 dilution. For titrations of seropositive and seronegative samples, threshold values for each dilution were calculated as the average of negative samples plus 3 times the standard deviation. Titrated samples were initially diluted 1:100 and then serially diluted 1:3 (final dilution of 1:8,100). Serum dilutions were made in PBS with 1% milk and added to RBD-coated and blocked wells. OD 450 values for each species and titrations were graphed in Prism ver. 8 (GraphPad Software, San Diego, CA, USA).

Western and dot blots. For dot blots, 5 to 10 mL of sample was applied directly onto nitrocellulose membranes and allowed to dry. Western blots were loaded with 30 mL (;3 mg) of purified recombinant RBD, resolved in a 12% SDS-PAGE gel, and transferred to a nitrocellulose membrane. Blots were blocked overnight at 4°C with 5% milk in PBS. Mouse anti-6ÂHis-HRP conjugated antibody (1:5,000) (Proteintech, Rosemont, IL, USA) or polyclonal serum samples (1:20) were incubated with the blots at room temperature for 2 h and subsequently washed 2 times with TBS-T (tris buffered saline with 0.1% Tween 20) . For polyclonal serum, species-specific HRP anti-IgG antibodies (1:5,000 dilution) were incubated for an additional 2 h and washed 2 times as described above. Chemiluminescent substrate (Pierce SuperSignal West Pico PLUS; Thermo Fisher, USA) was added, and luminescence was detected using ChemiDoc (Bio-Rad, Hercules, CA, USA).

Neutralization assays. Serum samples were screened for neutralization using LEGENDplex SARS-CoV-2 neutralizing antibody assay (BioLegend, San Diego, CA, USA) following the manufacturer's recommendations. Briefly, serum was diluted 1:100 and incubated with biotinylated SARS-CoV-2 S1 subunit containing the RBD and human ACE-2 (hACE-2) conjugated to fluorescent beads. Streptavidin-PE (phycoerythrin) was added to detect SARS-CoV-2 S1 subunit bound to beads/hACE-2. Binding/PE levels were detected via a BD LSR-II instrument equipped with 488-and 633-nm lasers (Becton, Dickinson, Franklin Lakes, NJ, USA). Data were analyzed using BioLegend LEGENDplex data analysis software. Mean fluorescent intensity (MFI) was normalized and graphed in Prism ver. 9 (GraphPad Software, San Diego, CA, USA).

Fecal coronavirus PCR screen and sequence alignments. Deidentified fecal samples from 30 healthy East Tennessee cats were collected and stored at 280°C. Samples were resuspended in PBS to yield a 10% solution and centrifuged to clarify. Fecal RNA was extracted using a viral RNA extraction kit (Qiagen, Hilden, Germany), and RNA was reverse transcribed using a Verso cDNA kit with random hexamers and RT enhancer (Thermo Fisher, Waltham, MA, USA). PCR amplification of conserved coronavirus regions using previously reported primer pairs was used to screen the cDNA (62) . PCR amplicons were visualized on a 1% agarose gel, and positive PCR samples were Sanger dideoxy sequenced. Sequences were viewed using 4Peaks software (Nucleobytes, Amsterdam, Netherlands). Sequences from fecal samples were Clustal W aligned to common coronaviruses and trimmed, and phylogenetic trees were generated using the maximum-likelihood method for each positive loci using MEGA X (72, 73) . For phylogenetic trees using multiple loci, aligned and trimmed sequences for each loci were concatenated together prior to maximum-likelihood tree construction. Phylogenetic trees were tested by bootstrap testing with 1,000 iterations. Common coronavirus sequences for ORF1ab (RdRp and helicase loci) and spike were obtained from the following: porcine coronavirus HKU15 (GenBank accession number NC039208), SARS-CoV-2 (MN988668), SARS-CoV (NC004718), porcine respiratory coronavirus/PRCoV (KY406735), human coronavirus OC43 (NC006213), MERS-CoV (NC038294), feline coronavirus/FCoV (NC002306), canine respiratory coronavirus/CRCoV (KX432213), canine coronavirus/CCoV (JQ404410), bovine coronavirus/BCoV (NC003045), avian coronavirus (NC048214), human coronavirus 229E (NC002645), transmissible gastroenteritis virus/TGEV (NC038861), murine hepatitis virus/MHV (NC048217), human coronavirus NL63 (NC005831), feline coronavirus strain UU8 (FJ938055), feline coronavirus strain UU19 (HQ392470), feline coronavirus strain Black (EU186072), feline coronavirus strain RM (FJ938051), and feline coronavirus strain Felix (MG893511).

Data availability. All generated sequences were deposited in GenBank under accession numbers MZ220722 through MZ220762 (sample ID, positive loci, animal location, and accession numbers are shown in Table 2 ). Data are available upon request for peer review.

Statistics. All graphs and statistical analyses were performed in Prism ver. 9 (GraphPad Software, San Diego, CA, USA). ELISA OD 450 results were normalized to an interplate replicate run with all assays. Student's one-tailed t tests with Welch's correction and one-way analysis of variance (ANOVA) with multiple-comparison tests were performed on ELISA results and documented in the figure legends. Descriptive statistics were provided for each ELISA group (mean, median, and quartiles). Receiver operator curve (ROC) analysis was performed to determine appropriate threshold values for human, cat, and deer serum samples. The area under the curve was calculated for each titrated ELISA sample and graphed. Neutralization data were normalized with the negative-control group (normal cat serum) representing 100% MFI.

Emergence of a novel human coronavirus threatening human health

Clinical characteristics of coronavirus disease 2019 in China

Origin and cross-species transmission of bat coronaviruses in China

Emergence of SARS-CoV-2 through recombination and strong purifying selection

The proximal origin of SARS-CoV-2

Prolonged persistence of SARS-CoV-2 RNA in body fluids

Transmission of SARS-CoV-2: a review of viral, host, and environmental factors

Detection of SARS-CoV-2 in different types of clinical specimens

Detection and isolation of SARS-CoV-2 in serum, urine, and stool specimens of COVID-19 patients from the Republic of Korea

Probable evidence of fecal aerosol transmission of SARS-CoV-2 in a highrise building

Infectious SARS-CoV-2 in feces of patient with severe COVID-19

Evidence of airborne transmission of the severe acute respiratory syndrome virus

Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome

Experimental infection of domestic dogs and cats with SARS-CoV-2: pathogenesis, transmission, and response to reexposure in cats

Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2

Broad host range of SARS-CoV-2 and the molecular basis for SARS-CoV-2 binding to cat ACE2

Detection of SARS-CoV-2 in a cat owned by a COVID-19-affected patient in Spain

High prevalence of SARS-CoV-2 antibodies in pets from COVID-191 households

Infection of dogs with SARS-CoV-2

Evidence of exposure to SARS-CoV-2 in cats and dogs from households in Italy

SARS-CoV-2 in quarantined domestic cats from COVID-19 households or close contacts

Transmission of SARS-CoV-2 in domestic cats

Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans

Virology: SARS virus infection of cats and ferrets

Possible role of an animal vector in the SARS outbreak at Amoy Gardens

Animal-to-human SARS-associated coronavirus transmission?

SARS-CoV-2 infection in free-ranging white-tailed deer

Multiple spillovers from humans and onward transmission of SARS-CoV-2 in white-tailed deer

SARS-CoV-2 exposure in wild white-tailed deer (Odocoileus virginianus)

A serological assay to detect SARS-CoV-2 seroconversion in humans

Antibody responses to SARS-CoV-2 in patients with COVID-19

The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

Rapid generation of neutralizing antibody responses in COVID-19 patients

Experimental feline enteric coronavirus infection reveals an aberrant infection pattern and shedding of mutants with impaired infectivity in enterocyte cultures

Pathogenic characteristics of persistent feline enteric coronavirus infection in cats

SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis

Use of a reverse-transcriptase polymerase chain reaction for monitoring the shedding of feline coronavirus by healthy cats

A serological survey of SARS-CoV-2 in cat in Wuhan

Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome

Disappearance of antibodies to SARS-associated coronavirus after recovery

Duration of serum neutralizing antibodies for SARS-CoV-2: lessons from SARS-CoV infection

Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study

Biochemical characterization of SARS-CoV-2 nucleocapsid protein

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection

Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection

Neutralizing antibody responses in COVID-19 convalescent sera

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

A structural landscape of neutralizing antibodies against SARS-CoV-2 receptor binding domain

Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD

Crossreactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals

Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections

Serological screening for coronavirus infections in cats

Serological survey of SARS-CoV-2 for experimental, domestic, companion and wild animals excludes intermediate hosts of 35 different species of animals

SARS-CoV-2 serological survey of cats in China before and after the pandemic

SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup

Production of trimeric SARS-CoV-2 spike protein by CHO cells for serological COVID-19 testing

Susceptibility of white-tailed deer (Odocoileus virginianus) to SARS-CoV-2

Identification of a novel coronavirus in bats

Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana

Neutralizing antibodies targeting SARS-CoV-2 spike protein

Possibility for reverse zoonotic transmission of SARS-CoV-2 to freeranging wildlife: a case study of bats

Detection of group 1 coronaviruses in bats in North America

Detection of polyoma and corona viruses in bats of Canada

Alphacoronaviruses in New World bats: prevalence, persistence, phylogeny, and potential for interaction with humans

Occurrence and frequency of coronavirus infections in humans as determined by enzyme-linked immunosorbent assay

Rises in titers of antibody to human coronaviruses OC43 and 229E in Seattle families during 1975-1979

SARS-CoV-2 infection and transmission in the North American deer mouse

CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice

MEGA X: Molecular Evolutionary Genetics Analysis across computing platforms

We thank the following for their generous contributions that made this work possible: